#263 – John Abramson: Big Pharma

Theme 1: Knowledge Control — The "Ultimate Power" Beyond Money

John Abramson argues that the most central and insidious way the pharmaceutical industry undermines the U.S. healthcare system is by controlling "what doctors believe to be correct medical knowledge."

• Mechanism Breakdown: Doctors are trained to trust "evidence-based medicine" — i.e., peer-reviewed journal articles and clinical practice guidelines. But Abramson points out that both layers of trust have failed.
• Blind Spot of Peer Review: Reviewers only see the manuscript submitted by the drug company, without the ability to independently access raw data. He cites the Vioxx (万络) case: in a study published by Merck in the New England Journal of Medicine in 2000, 3 heart attacks were deliberately concealed. The study had 12 authors, of whom 10 academic authors were completely unaware because they had never seen the data. Those 3 events were enough to flip the statistical conclusion from "no significant risk" to "significantly increased risk."
• Dilemma of Clinical Guidelines: Guideline developers typically rely on unverified abstracts that have already been "filtered" by drug companies and journals, rather than independently analyzing raw data. Abramson emphasizes that for doctors, once knowledge is published, it becomes "sticky" and very difficult to correct.
• Data and Analogy: Abramson uses a sports analogy to describe this systemic flaw — "a basketball game without referees, letting the players call their own fouls." The U.S. healthcare system is the only wealthy country that lacks such a "knowledge referee."

---

Theme 2: The Truth of Advertising — From "Information" to "Manipulation"

Abramson and host Lex Fridman agree that the key issue with pharmaceutical advertising (whether direct-to-consumer or to physicians) is not whether it is illegal, but rather its "systematic misleading."

• Specific example: Trulicity (dulaglutide). This drug is a diabetes injection costing about $6,200/year, while the equally effective metformin costs only $4/month. Its advertising highlights "reducing cardiovascular risk," but Abramson reveals:
• Number Needed to Treat (NNT): 323 people need to be treated to prevent one non-fatal event, at a cost of $2.7 million. The advertisement does not mention this data.
• Missing comparator: The drug has never been directly compared head-to-head with lifestyle interventions (such as diet and exercise). However, a 1990s NIH-funded "Diabetes Prevention Program" study showed that intensive lifestyle intervention can reduce diabetes risk by 58%, far exceeding metformin's 31%. Abramson points out that the ultimate purpose of advertising is to "sell drugs," not to "prevent disease."
• Implications for Chinese audiences: China has not yet liberalized direct-to-consumer prescription drug advertising, but the logic of academic promotion targeting physicians (cash-for-sales, sponsored conferences) is similar. Abramson's critical perspective—focusing on "whether information is complete and whether it is deliberately filtered"—remains an effective framework for analyzing similar issues.

---

Theme 3: Cross-Border Gaming and Market Failure — The Case of the COVID-19 Vaccine

Abramson argues that in the COVID-19 vaccine case, massive profits (Pfizer projected $65 billion in sales for the first two years, far exceeding the $20 billion peak of the previous global best-selling drug Humira) directly led to the failure of global public health governance.

• Historical Context: Abramson emphasizes that the key infrastructure work for mRNA vaccines was completed by the NIH as early as 2016. Pfizer voluntarily paid royalties to the NIH, avoiding a legal dispute with Moderna. However, the problem for the U.S. government was that when investing huge sums in Operation Warp Speed, it did not require companies to include global vaccine distribution in the agreements.
• Data Chain: 85% of early vaccines flowed to the First World. In May 2021, the WTO, WHO, IMF, and World Bank jointly called for raising $50 billion to achieve a 40% vaccination rate in the Third World by year-end, but the call went unanswered. The wealth gains from vaccines for 32 billionaires at that time also amounted to exactly $50 billion.
• Deduction and Falsification: Abramson believes that failing to vaccinate the Third World will lead to the continuous emergence of variant strains that will backfire on the U.S., with Delta and Omicron being the evidence. Falsification Signal: If global vaccine distribution is made one of the core KPIs for pharmaceutical companies, and if the agreements between pharmaceutical companies and governments include global equity clauses, then this judgment may be weakened. Readers should note that this is a critic's perspective; pharmaceutical companies would argue that their duty is to maximize shareholder returns, not to solve global health governance issues.
• High-Risk Insight: Abramson strongly questions the actions of the FDA and Pfizer in refusing to accelerate the disclosure of vaccine clinical trial data at a cost of $3 million (approximately equal to two hours of Pfizer's vaccine sales) and offers a "10-to-1 bet" that the data must contain content embarrassing for both parties. He also emphasizes that he is not anti-vaccine, but advocates for "data transparency."

---

Theme 4: Systemic Regulatory Capture and Structural Issues

Abramson argues that from the FDA to Medicare, institutional design has been deeply infiltrated by pharmaceutical industry interests, creating two structural cancers: the "revolving door" and "non-negotiated pricing."

• Case: Aduhelm (aducanumab). The FDA's scientific advisory committee voted 10:0 against, with one abstention, to reject this Alzheimer's drug (as evidence showed it was ineffective and harmful, with 33% of trial patients experiencing brain swelling). Yet the FDA approved it over that vote. Three committee members resigned in protest. Even more striking, the director of the FDA's Center for Drug Evaluation and Research stated that the agency should "relax" the financial conflict-of-interest restrictions on advisory committee members in order to obtain "less emotional responses." Abramson views this as a perfect example of how "pharmaceutical industry thinking has permeated regulatory agencies."
• Structural "Chronic Disease" : Medicare is legally prohibited from negotiating drug prices with manufacturers—a unique feature in the U.S. When this provision was passed in 2003, the key sponsor, Representative Billy Tauzin, resigned immediately after the bill's passage and joined the pharmaceutical industry in a position worth $2 million per year.
• Reform Proposal : Abramson explicitly supports a "double ban" : banning pharmaceutical executives from serving in regulatory agencies and vice versa; and repealing the provision that prohibits Medicare from negotiating drug prices with manufacturers (i.e., allowing the government to negotiate).

---

Mentioned Stocks

Stock	Guest Stance	Key Data
Pfizer	Risk Warning / Criticism (Lack of data transparency, profit-driven)	Estimated vaccine sales of $65 billion in the first two years; fined $3.8 billion for fraud (1991-2017); jury found it guilty of fraud and racketeering in 2010
Merck	Risk Warning / Criticism (Data manipulation)	Intentionally concealed 3 heart attacks in Vioxx study; the drug triggered the largest drug recall in U.S. history
Biogen	Risk Warning / Criticism (Approval of ineffective drug)	Advisory committee voted 10:0 against approving Adjahelm; drug ineffective and 33% of patients developed brain edema
Lilly	Risk Warning / Criticism (Misleading advertising)	Trulicity annual cost $6,200, NNT of 323 patients, cost of $2.7 million

---

Judgments Worth Remembering

1. Knowledge control is the ultimate power of pharmaceutical companies (Abramson): The biggest problem with drug companies is not high prices, but that they determine what medical knowledge doctors consider "correct". Peer review and clinical guidelines are based on summaries provided by drug companies that have not been independently verified, trapping doctors in an "information cage".

2. Trulicity's advertising demonstrates the absence of the "number needed to treat" (Abramson): 323 people need to be treated to prevent one non-fatal event, at a cost of $2.7 million. If advertisements had to disclose this data and compare it with lifestyle interventions, their effectiveness would be severely diminished.

3. The concealment of Vioxx data is a classic case of "selective publication" (Abramson): Merck deliberately omitted 3 heart attacks from the paper published in the New England Journal of Medicine; these 3 events were enough to change the statistical conclusion. The 10 academic authors were completely unaware, as they had never seen the original data.

4. The failure of global vaccine distribution stems from a narrow "profit maximization" model (Abramson): The U.S. government invested heavily but did not require drug companies to make global equitable distribution a part of the agreement. As a result, the wealth increase of 32 billionaires ($50 billion) exactly equals the funding global public health experts called for to prevent the emergence of new variants. Falsification signal: This judgment would be challenged if a drug company proactively ties global distribution to profit in an agreement.

5. Antidepressants are over-medicalized (Abramson): Antidepressants are effective for major depression (NNT of about 4, meaning 1 in 4 people significantly improves), but they are ineffective for the majority of patients who lack the diagnostic criteria for "major". Drug companies have medicalized "sadness within the normal range" into a "disease", while the fundamental solution should be to "respect the patient's pain, then identify the root cause of the pain" (e.g., marital problems, trauma, socioeconomic difficulties), rather than immediately prescribing medication.

6. "Banning the revolving door" and "allowing Medicare to negotiate drug prices" are two key reforms (Abramson): The Aduhelm case proves that when regulators lack vigilance against conflicts of interest with drug companies, they make decisions that "violate scientific consensus". The prohibition on Medicare negotiating drug prices is one of the core reasons why "the U.S. spends 18% of its GDP on healthcare yet achieves only inefficient health outcomes."

7. "The meaning of life is dedication" (Abramson): When asked about death and the meaning of life, his answer was: "Care about something, and give it your all." This both echoes the dedication required of physicians and underpins the values behind his critique of the pharmaceutical industry's "profit-first" culture.